Breaking News Instant updates and real-time market news.

ACAD

ACADIA

$36.89

1.09 (3.04%)

, ACOR

Acorda Therapeutics

$27.25

0.05 (0.18%)

13:10
03/06/17
03/06
13:10
03/06/17
13:10

Cowen to hold a conference

37th Annual Healthcare Conference is being held in Boston on March 6-8 with webcasted company presentations to begin on March 6 at 1:20 pm; not all company presentations may be webcasted. Webcast Link

ACAD

ACADIA

$36.89

1.09 (3.04%)

ACOR

Acorda Therapeutics

$27.25

0.05 (0.18%)

ACHI

Accretive Health

$2.43

0.08 (3.40%)

BAX

Baxter

$50.81

-0.1 (-0.20%)

BMY

Bristol-Myers

$56.99

-0.27 (-0.47%)

OVAS

OvaScience

$1.52

0.03 (2.01%)

NVET

Nexvet Biopharma

$3.35

0.15 (4.69%)

RHHBY

Roche

SHPG

Shire

$186.30

1.8 (0.98%)

EYES

Second Sight

$1.55

0.02 (1.31%)

CRIS

Curis

$2.38

-0.03 (-1.24%)

AZN

AstraZeneca

$29.77

-0.15 (-0.50%)

ARAY

Accuray

$5.45

0.1 (1.87%)

AMAG

AMAG Pharmaceuticals

$23.10

-0.25 (-1.07%)

BIIB

Biogen

$297.85

4.26 (1.45%)

BCR

C.R. Bard

$246.77

0.98 (0.40%)

TIG

TiGenix

$14.86

0.36 (2.48%)

ALDX

Aldeyra

HRC

Hill-Rom

$65.55

-0.58 (-0.88%)

ITEK

Inotek Pharmaceuticals

EPZM

Epizyme

$15.00

1.15 (8.30%)

LBIO

Lion Biotechnologies

$7.65

-0.4 (-4.97%)

LMAT

LeMaitre

$22.26

0.14 (0.63%)

ADRO

Aduro Biotech

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 09

    Mar

  • 09

    Mar

  • 09

    Mar

  • 14

    Mar

  • 16

    Mar

  • 17

    Mar

  • 21

    Mar

  • 29

    Mar

  • 01

    Apr

  • 27

    Apr

  • 26

    Jun

ACAD ACADIA
$36.89

1.09 (3.04%)

11/11/16
11/11/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aegerion (AEGN) resumed with a Neutral at JPMorgan. 2. Lamb Weston (LW) initiated with a Buy at Stifel, initiated with an Overweight at Barclays, and an Equal Weight at Morgan Stanley. 3. bluebird bio (BLUE) initiated with a Market Perform at BMO Capital. 4. Alder Biopharmaceuticals (ALDR) initiated with an Outperform at BMO Capital. 5. ACADIA (ACAD) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/16
LEER
12/20/16
NO CHANGE
LEER
Market Perform
ACADIA data a 'clear upside' but benefit looks modest, says Leerink
Leerink analyst Paul Matteis notes that ACADIA has announced positive top-line data from its Phase 2 study of pimavanserin in Alzheimer's Disease Psychosis. While the analyst believes the benefit looks "modest," he says the announcement represents "clear upside to expectations," which were low into the event. Leerink has a Market Perform on the shares.
12/21/16
PIPR
12/21/16
NO CHANGE
PIPR
Piper lays out top BioPharma picks for 2017
Piper Jaffray analysts laid out their top BioPharma picks for 2017. Analyst Richard Purkiss favors Pfizer (PFE) and Eli Lilly (LLY) as his top large pharma picks. Analyst Joshua Schimmer calls Gilead (GILD) and Alexion (ALXN) his top large cap picks. Analyst David Amsellem names Horizon Pharma (HZNP) his top specialty pharma pick. Piper's other top Biopharma picks for 2017 include ACADIA (ACAD), Aimmune (AIMT), Akorn (AKRX), Alnylam (ALNY), Axovant Sciences (AXON), Cara Therapeutics (CARA), CoLucid Pharmaceuticals (CLCD), Eale Pharmaceuticals (EGRX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Neurocrine (NBIX), Nektar (NKTR), Otonomy (OTIC), Reata Pharmaceuticals (RETA), Rigel Pharmaceuticals (RIGL), Ignyta (RXDX), Theravance Biopharma (TBPH), Versartis (VSAR) and Voyager Therapeutics (VYGR). The analysts look for recent momentum in BioPharma to continue in 2017. They believe innovation and potentially repatriation should lead to increased merger activity.
03/01/17
LEER
03/01/17
NO CHANGE
Target $36
LEER
Market Perform
ACADIA price target raised to $36 from $31 at Leerink
Leerink analyst Paul Matteis raised his price target for ACADIA to $36 from $31 to reflect quarterly updates and solid sales growth, and greater weight to his revenue multiple analysis. The analyst reiterates a Market Perform rating on the shares.
ACOR Acorda Therapeutics
$27.25

0.05 (0.18%)

02/15/17
GSCO
02/15/17
UPGRADE
Target $22
GSCO
Neutral
Acorda Therapeutics upgraded to Neutral from Sell at Goldman
Goldman Sachs analyst Salveen Richter upgraded Acorda Therapeutics to Neutral saying recent positive data for CVT-301 in Parkinson's removes a worst-case scenario with a potential 2018 market entry to offset Ampyra. The analyst raised his price target for the shares to $22 from $16.
02/15/17
02/15/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Parker-Hannifin (PH) upgraded to Buy from Neutral at BofA/Merrill, with analyst Andrew Obin saying he sees significant earnings upside in the coming years from cyclical upside from an industrial recovery combined with the operating turnaround story and integration of Clarcor. 2. Nordson (NDSN) upgraded to Overweight from Sector Weight at KeyBanc, with analyst Jeffrey Hammond saying that despite concerns, he believes Nordson's Advanced Technology story has legs given improving semiconductor capex in 2017, meaningful business wins with Chinese smartphone makers pushing for greater automation, and diversification through on-wafer dispense and inspection systems as well as in Medical and Industrial. 3. Acorda Therapeutics (ACOR) upgraded to Neutral from Sell at Goldman, with analyst Salveen Richter saying recent positive data for CVT-301 in Parkinson's removes a worst-case scenario with a potential 2018 market entry to offset Ampyra. 4. On Assignment (ASGN) upgraded to Outperform from Market Perform at Avondale, with analyst Randle Reece saying he expects IT staffing to to lead the U.S. staffing industry in 2017-18 growth, driven by agency staffing demand in large vertical markets such as technology and financial services, and emerging drivers. 5. Brady (BRC) upgraded to Buy from Neutral at Northcoast by analyst Keith Housum, who says he is confident guidance and consensus estimates will move higher given improving operations resulting in lower SG&A, improving revenue expectations and a strengthening balance sheet resulting in lower interest expense. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here
02/09/17
STFL
02/09/17
NO CHANGE
STFL
Acorda Therapeutics data positive, says Stifel
Stifel analyst Thomas Shrader says that the data on Acorda's CVT-301 drug was "clearly positive." The analyst raised his price target on the stock to $30 from $28 and keeps a Buy rating.
02/09/17
LEER
02/09/17
NO CHANGE
LEER
Market Perform
Acorda Therapeutics Phase 3 data 'solid,' says Leerink
Leerink analyst Paul Matteis notes that Acorda Therapeutics' positive Phase 3 data of CVT-301 showing a statistically significant improvement in motor function in patients with Parkinson's disease was mostly expected. While the analyst says the data is "solid," he points out that it was not "as pristine" as Phase 2. He reiterates a Market Perform on the shares.
ACHI Accretive Health
$2.43

0.08 (3.40%)

BAX Baxter
$50.81

-0.1 (-0.20%)

10/13/16
WELS
10/13/16
INITIATION
WELS
Outperform
Baxter initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Baxter International with an Outperform rating and $53-$55 price target range. The analyst sees "significant balance sheet optionality" for the company to further enhance its organic growth via acquisition and/or sizeable share repurchase programs.
10/13/16
10/13/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aaron's (AAN) initiated with a Buy at Jefferies. 2. eBay (EBAY) and Etsy (ETSY) coverage assumed with a Neutral at Wedbush. 3. Five Below (FIVE) and Dollar Tree (DLTR) were initiated with an Overweight at KeyBanc while the firm initiated Dollar General (DG) with a Sector Weight. 4. Baxter (BAX) initiated with an Outperform at Wells Fargo. 5. Symantec (SYMC) initiated with an Outperform at FBN Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/15/16
LEHM
09/15/16
INITIATION
Target $52
LEHM
Overweight
Baxter reinstated with an Overweight at Barclays
Barclays analyst Matthew Taylor reinstated Baxter International with an Overweight rating and $52 price target. The analyst sees upside to the company's long-term growth and margin targets.
06/24/16
PIPR
06/24/16
NO CHANGE
PIPR
Medical equipment makers' exposure to U.K. 'manageable,' says Piper Jaffray
Piper Jaffray analyst Matt O'Brien estimated that the direct exposure to the U.K. of the medical equipment names in the firm's coverage with the largest Euro/Pound exposure is roughly 5%, which he believes is "manageable." The names in the space with the largest Euro/Pound exposure are Dentsply Sirona (XRAY) Cooper (COO), K2M Group (KTWO), Globus Medical (GMED), ResMed (RMD), Zimmer Biomet (ZBH), Edwards Lifesciences (EW) and Baxter (BAX), said O'Brien, who added that manufacturing may help lessen the impact for Zimmer, Edwards, Baxter and Cooper.
BMY Bristol-Myers
$56.99

-0.27 (-0.47%)

01/30/17
FBCO
01/30/17
NO CHANGE
Target $52
FBCO
Neutral
Bristol-Myers price target lowered to $52 from $61 at Credit Suisse
Credit Suisse analyst Vamil Divan lowered his price target for Bristol-Myers to $52 from $61 following Q4 results. Given the recent update that the company will not pursue an accelerated pathway for the Opdivo+Yervoy combo in first-line non-small cell lung cancer, the analyst does not see many fundamental reasons for upside to Bristol-Myers in the coming months. He reiterates a Neutral rating on the shares.
02/01/17
GSCO
02/01/17
NO CHANGE
GSCO
Bristol-Myers estimates trimmed for Sprycel loss at Goldman
Goldman reduced Bristol-Myers earnings estimates by 4c-7c for 2017-2021 to reflect the lost of the Sprycel appeal in the EU. The firm continues to rate Bristol-Myers a Buy.
02/15/17
DBAB
02/15/17
NO CHANGE
DBAB
Deutsche not seeing Pfizer buying Bristol-Myers at this time
Following yesterday's speculation of a potential deal, Deutsche Bank analyst Gregg Gilbert said he would be surprised to see Pfizer (PFE) make a move on Bristol-Myers Squibb (BMY) at this stage. Such an acquisition "would represent a very large and concentrated opportunity/risk on immuno-oncology, an area fraught with near-term uncertainty," Gilbert told investors last night in a research note. He believes that if Pfizer were to use $90B for a deal, it would prefer to acquire a more diverse set of value drivers. The analyst keeps a Hold rating on Bristol and Buy rating on Pfizer. Bristol shares rose 3% yesterday to $53.71 amid speculation of a potential takeover. The conjecture had Roche (RHHBY), Novartis (NVS) and Pfizer potentially looking into a bid for Bristol.
03/06/17
FBCO
03/06/17
NO CHANGE
FBCO
Near-Term acquisition of Bristol-Myers unlikely, says Credit Suisse
Credit Suisse analyst Vamil Divan says there is increasing investor focus on strategic actions and opportunities around Bristol-Myers (BMY) following the company's recent stumbles and the increased stake activist investors have taken in the stock. The analyst notes that "the big question" remains whether any of its peers may be interested in an outright acquisition, with Pfizer (PFE), Novartis (NVS) and Gilead (GILD) among the possible acquirers. While the numbers may make sense, Divan sees an acquisition in the next 9-12 months as unlikely as he needs more clarity on some of the large unknowns in the lung cancer market and macro issues such as corporate tax reform.
OVAS OvaScience
$1.52

0.03 (2.01%)

12/07/16
OPCO
12/07/16
INITIATION
OPCO
Perform
OvaScience assumed with a Perform at Oppenheimer
Oppenheimer analyst Derek Archila assumed coverage of OvaScience with a Perform rating citing a lack of revenue visibility.
NVET Nexvet Biopharma
$3.35

0.15 (4.69%)

RHHBY Roche

02/28/17
PIPR
02/28/17
UPGRADE
Target $65
PIPR
Overweight
Piper upgrades Bioverativ to Overweight after emicizumab trial death
Piper Jaffray analyst Joshua Schimmer last night upgraded Bioverativ (BIVV) to Overweight from Neutral and raised his price target for the shares to $65 from $44. The analyst sees an improved outlook for the durability of the company's Eloctate franchise following a patient death in Roche's (RHHBY) emicizumab clinical trial in hemophilia patients with inhibitors. The hemophilia community will likely wait for more safety data before adopting a new therapy with potentially serious safety signals, Schimmer tells investors in a research note. He believes emicizumab's setback creates "some breathing room" for Bioverativ to continue to execute.
03/02/17
JPMS
03/02/17
NO CHANGE
JPMS
Overweight
Puma best-case off table with positive Roche study, says JPMorgan
JPMorgan analyst Cory Kasimov says that while Roche's (RHHBY) positive Aphinity trial results take the near-term best-case scenario off the table for Puma Biotechnology (PBYI), the ultimate impact on Puma "remains to be seen." The future of Puma's neratinib in the adjuvant breast cancer setting largely rests on the nuances of the Roche data, namely the magnitude of benefit, the subgroups that drive the benefit and details of the safety profile, Kasimov tells investors in a research note while pointing out that Roche's press release is light on details. The analyst initially expected that positive Aphinity results would take a third of the value out of Puma shares. Kasimov adds, however, that investor feedback this morning suggests the selloff could provide an opportunity ahead of Aphinity study details at ASCO and pending neratinib data points in first half of 2017. Puma shares are down 25%, or $9.50, to $29 in pre-market trading. Roche shares are up 6% to $32.30.
03/02/17
RBCM
03/02/17
NO CHANGE
RBCM
Puma Biotechnology price target lowered to $17 from $57 at RBC Capital
RBC Capital analyst Simos Simeonidis cut the price target on Puma (PBYI) twice in one day, first to $48 from $57 and then to $17 from $48. The analyst says that, in the wake of positive data on Roche's (RHHBY) breast cancer treatment,Perjetab, reported this morning, "the commercial opportunity for (Puma's) neratinib in the extended adjuvant setting should be considered as (most likely) eliminated." The analyst adds that GI concerns about Puma's drug increase the likelihood of it not being used in the extended adjuvant setting. Simeonidis expects Puma to attempt to market neratinib in the EU and the rest of the world on its own. He keeps a Sector Perform rating on the name.
03/02/17
SBSH
03/02/17
NO CHANGE
Target $88
SBSH
Buy
Citi sees 'significant upside' in Puma shares, says buy the selloff
Citi analyst Yigal Nochomovitz recommends using this morning's selloff in shares of Puma Biotechnology (PBYI) as a buying opportunity. The stock in pre-market trading is down 24%, or $9.25, to $28.80. The Roche (RHHBY) press release does not provide any numbers on magnitude of benefit or any details on benefit in subgroups, Nochomovitz tells investors in a research note after the Aphinity trial met its endpoint. The analyst adds that today's press release does not definitively state Roche will be filing on the data, rather noting that, "These data will be discussed with health authorities across the world, including the US FDA with the hope to convert the current US accelerated approval to a full approval." It is hard to ignore the word choice of "hope" as opposed to "expectation," Nochomovitz contends. He continues to expect Puma's neratinib to receive FDA approval by the action date in July for extended adjuvant. The analyst said he sees "significant upside" in the shares. Further, Nochomovitz thinks Puma's breast cancer opportunities outside of adjuvant can justify the current valuation without any extended adjuvant revenue. He has a Buy rating on Puma with an $88 price target.
SHPG Shire
$186.30

1.8 (0.98%)

12/02/16
SOCG
12/02/16
INITIATION
SOCG
Buy
Shire initiated with a Buy at Societe Generale
12/02/16
12/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Exxon Mobil (XOM) initiated at BMO Capital. 2. Pfizer (PFE) initiated with a Neutral at Guggenheim. 3. DuPont Fabros (DFT) initiated with a Neutral at Guggenheim. 4. Acadia (ACHC) resumed with a Buy at Jefferies. 5. Shire (SHPG) initiated with a Buy at Societe Generale. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/19/17
01/19/17
NO CHANGE

Shire's application for ADHD disorder candidate acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. SHP465 is being evaluated as a potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder. The FDA is expected to provide a decision on or around June 20. Shire resubmitted the NDA for SHP465 in response to the Approvable Letter from the FDA that requested additional clinical studies and classified the response as a Class 2 resubmission with a review goal of six months. Launch is planned for the second half of 2017.
12/06/16
UBSW
12/06/16
DOWNGRADE
UBSW
Neutral
Shire downgraded to Neutral from Buy at UBS
EYES Second Sight
$1.55

0.02 (1.31%)

CRIS Curis
$2.38

-0.03 (-1.24%)

05/05/16
COWN
05/05/16
INITIATION
COWN
Outperform
Curis coverage assumed with an Outperform at Cowen
AZN AstraZeneca
$29.77

-0.15 (-0.50%)

02/21/17
BREN
02/21/17
NO CHANGE
BREN
AstraZeneca 'turnaround..approaching,' says Berenberg
Bernberg analyst Alistair Campbell lowered his 2017 EPs estimate for AstraZeneca to nearly 50% below consensus levels, citing faster erosion of legacy drugs. However, the analyst expects the company to make deals that will raise its EPS above this level, and he says that the company will report a great deal of news in 2017. Moreover, he says that data on the company's Lynparza drug for breast cancer was positive, giving it a "good start," while the company's pipeline and new drugs should enable it to resume growing within the next two years. Campbell says that the company's "turnaround is approaching," and he keeps a Buy rating on the shares.
02/17/17
WBLR
02/17/17
NO CHANGE
WBLR
Outperform
William Blair estimates $102/share buyout value for SAGE
After SAGE Therapeutics (SAGE) CEO Jeff Jonas noted during an interview yesterday that his company has received takeover interest, William Blair analyst Tim Lugo made some estimates on what SAGE could garner in a takeout scenario. An acquisition is unlikely before the Phase III studies set to report out through midyear as well as several other proof-of-concept studies, Lugo cautions. He believes, however, that the company's "strong pipeline of central nervous system targeting therapies" would be complementary to a number of larger companies, including Allergan (AGN), AstraZeneca (AZN) and potentially Biogen (BIIB). When using comparable acquisitions of companies in the pre-commercial phase with a median premium of 55% to the prior close and a 2.8 times enterprise value to his peak sales estimate of $1.5B, Lugo arrives at potential takeover value for SAGE of $102 per share, or a $4.2B enterprise value. Using a sum-of-the-parts analysis, the analyst arrives at a fair-value estimate between $95 and $100 per share. SAGE in early trading is down $2.36 to $60.39. Lugo has an Outperform rating on the stock.
01/12/17
PIPR
01/12/17
UPGRADE
Target $72
PIPR
Overweight
Merck upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss upgraded Merck (MRK) to Overweight saying he expects the FDA will conditionally approve the use of Keytruda plus chemo by May 10. Keytruda's adoption in first-line lung cancer would then be "substantially brought forward" to the initial detriment of Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY), Purkiss tells investors in a research note. The earlier than expected boost to Keytruda sales increases the analyst's 2017-2019 earnings forecasts for Merck by 12%-18%. Purkiss raised his price target for the shares to $72 from $63. The stock closed yesterday up $1.71 to $61.63.
01/30/17
SBSH
01/30/17
NO CHANGE
Target $151
SBSH
Buy
TESARO could be worth up to $238/share in a takeover, says Citi
Citi analyst Robyn Karnauskas estimates that TESARO (TSRO) could be valued at $208-$238 per share in a deal to be acquired. The stock closed Friday up 49c to $153.85. Multiple catalysts in TESARO's immune-oncology program throughout 2017 could cause investors to gain confidence and assign value to the program, Karnauskas tells investors in a research note. She keeps a Buy rating on the shares with a $151 price target. The analyst says she's been getting questions around the competitive landscape in the PARP space and potential M&A valuations ahead of the SOLO-2 data from AstraZeneca (AZN) expected in Q1.
ARAY Accuray
$5.45

0.1 (1.87%)

08/18/16
BMUR
08/18/16
NO CHANGE
Target $12
BMUR
Buy
Accuray downside limited, says Brean Capital
Brean Capital analyst Jason Wittes sees limited downside in Accuray despite mixed Q4 results. The analyst feels company guidance is conservative and that shares have been de-risked as backlog growth has improved. Wittes reiterated his Buy rating and $12 price target on Accuray.
02/06/17
AGIS
02/06/17
INITIATION
Target $7
AGIS
Buy
Accuray initiated with a Buy at Aegis
Aegis analyst Jason Wittes initiated Accuray (ARAY) with a Buy and a $7 price target saying Radixact, the next-generation TomoTherapy platform, was approved for 510k in June, and brings up to par with Varian's (VAR) True Beam and Elekta's Axesse machines. Wittes said Accuray is well positioned to take on its first major replacement cycle over the next three years, which we expect to add 40-50 systems a year to its current run rate of 60-70 systems.
12/14/16
JPMS
12/14/16
DOWNGRADE
Target $6
JPMS
Neutral
Accuray downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Tycho Peterson downgraded Accuray (ARAY) to Neutral citing a "sluggish" end market and the company's ongoing operational challenges. Accuray has not demonstrated consistent order growth or the ability to drive market share, Peterson tells investors in a research note. He lowered his price target for the shares to $6 from $8. The analyst's top picks in the Life Sciences space for 2017 are Agilent (A) and Thermo Fisher (TMO). Peterson this morning also downgraded Bruker (BRKR) to Underweight,
09/13/16
COWN
09/13/16
INITIATION
Target $9
COWN
Outperform
Accuray initiated with an Outperform at Cowen
Cowen analyst Joshua Jennings initiated Accuray with an Outperform rating as he believes the company is well positioned to benefit from two new product cycles and a burgeoning replacement opportunity. Jennings has a $9 price target on Accuray shares.
AMAG AMAG Pharmaceuticals
$23.10

-0.25 (-1.07%)

01/31/17
JPMS
01/31/17
NO CHANGE
Target $24
JPMS
Neutral
AMAG Pharmaceuticals price target lowered to $24 from $33 at JPMorgan
JPMorgan analyst Jessica Fye lowered her price target for AMAG Pharmaceuticals to $24 following updates at her firm's healthcare conference, including the shift in Makena strategy, Rekynda in-licensing and 2017 guidance. The analyst keeps a Neutral rating on the shares.
01/10/17
NEED
01/10/17
DOWNGRADE
NEED
Hold
AMAG Pharmaceuticals downgraded to Hold from Buy at Needham
01/10/17
01/10/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Moody's (MCO) was downgraded to Equal Weight from Overweight at Barclays and to Neutral from Buy at UBS. 2. Goldman Sachs (GS) and Comerica (CMA) were downgraded to Sell from Neutral at Citi. 3. T-Mobile (TMUS) downgraded to Neutral from Buy at MoffettNathanson. 4. AMAG Pharmaceuticals (AMAG) downgraded to Market Perform from Outperform at Leerink and to Neutral from Buy at Janney Capital. 5. BP (BP) downgraded to Market Perform from Outperform at BMO Capital analyst Brendan Warn citing his belief that the company will make a major acquisition this year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/03/17
COWN
02/03/17
DOWNGRADE
Target $25
COWN
Market Perform
AMAG Pharmaceuticals downgraded to Market Perform from Outperform at Cowen
Cowen analyst Ken Cacciatore downgraded AMAG Pharmaceuticals to Market Perform from Outperform on the belief that the franchise extension strategy for Makena will unfortunately fail. The analyst also questions the business decisions made after acquiring Makena, such as buying CBR, which could prove to be value destroying. Cacciatore lowered his price target to $25 from $35 on AMAG Pharmaceuticals shares.
BIIB Biogen
$297.85

4.26 (1.45%)

02/15/17
LEER
02/15/17
NO CHANGE
LEER
Biogen outlook intact despite Merck study suspension, says Leerink
Leerink analyst Geoffrey Porges notes that Merck (MRK) announced the suspension of the Phase 2/3 EPOCH trial of verubecestat in mild-to-moderate Alzheimer's patients for lack of efficacy, which was one of the most important catalysts for the field this year and a significant overhang for Biogen (BIIB) and other companies. While the failure had been widely anticipated in this study, the analyst believes this result does not read over to the outlook for Biogen's ongoing pivotal trials with aducanumab, or with its partner, Eisai's (ESALY) BACE inhibitor, elenbecestat.
02/15/17
LEER
02/15/17
INITIATION
Target $56
LEER
Outperform
Bioverativ initiated with an Outperform at Leerink
Leerink analyst Jason Gerberry initiated Bioverativ (BIVV) with an Outperform rating and $56 price target, citing the "underappreciated durability" of its marketed hemophilia assets, near-term projections that he views as beatable and the potential for tax reform or an M&A deal to unlock value. Bioverativ recently spun off from Biogen (BIIB) and "spins have a history of working," Gerberry added.
03/01/17
NOMU
03/01/17
INITIATION
Target $345
NOMU
Neutral
Biogen initiated with a Neutral at Nomura
Nomura initiated Biogen with a Neutral and a $345 price target.
BCR C.R. Bard
$246.77

0.98 (0.40%)

01/03/17
MSCO
01/03/17
UPGRADE
MSCO
Overweight
C.R. Bard upgraded to Overweight from Equal Weight at Morgan Stanley
01/05/17
01/05/17
UPGRADE
Target $265

Strong Buy
C.R. Bard upgraded to Strong Buy on organic growth stability at Raymond James
As previously reported, Raymond James upgraded C.R. Bard to Strong Buy from Outperform and raised its price target to $265 from $250. Analyst Lawrence Keusch said Bard is driving solid organic top-line growth with recent strength from market share gains in hernia, emerging markets and expansion of the DCB franchise and estimates 6% organic growth for 2017. Keusch said Bard generates 69% of sales in the US, which reduces exposure to the strengthening dollar, and has virtually no revenue from capital equipment, which eliminates any concerns of a slowdown in hospital spending.
01/05/17
RAJA
01/05/17
UPGRADE
RAJA
Strong Buy
C.R. Bard upgraded to Strong Buy from Outperform at Raymond James
01/03/17
MSCO
01/03/17
UPGRADE
Target $260
MSCO
Overweight
C.R. Bard upgraded to Overweight, growth to continue, says Morgan Stanley
As previously reported, Morgan Stanley upgraded C.R. Bard to Overweight from Equal Weight with a new $260 price target. Analyst David Lewis expects is positive on Bard's diversified and insulated growth and said the company is never reliant on any one product or division and expects new product cadence to continue in 2017. Lewis sees share gains in Surgical, Oncology, and broader emerging market growth as drivers and expects the earnings inflection that started in Q1 2016 to continue in 2017.
TIG TiGenix
$14.86

0.36 (2.48%)

01/09/17
COWN
01/09/17
INITIATION
COWN
Outperform
TiGenix initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated TiGenix with an Outperform rating given its compelling late-stage clinical data and clear regulatory path forward in major markets. EU approval is expected in the second half of 2017.
01/09/17
BOFA
01/09/17
INITIATION
Target $19
BOFA
Buy
TiGenix initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad initiated TiGenix with a Buy and a $19 price target saing its lead asset, Cx601 for treatment of complex perianal fistulas, or CPF, in Crohn's disease, could be paradigm shifting in treatment of CPF and expects partner Takeda to launch Cx601 in 2H17 if approved. The analyst sees peak world-wides risk-adjusted sales of $2247M in 2028.
01/09/17
ADAM
01/09/17
INITIATION
Target $22
ADAM
Buy
TiGenix initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated TiGenix with a Buy citing U.S. sales potential for its Crohn's drug candidate. He expects approval and a successful commercial launch. Newman has a $22 price target on TiGenix shares.
01/09/17
01/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Accenture (ACN) initiated with an Outperform at William Blair. 2. Coca-Cola European Partners was initiated with an Overweight at Barclays, while Coca-Cola (KO) and Dr Pepper Snapple (DPS) were initiated with an Equal Weight. 3. TiGenix (TIG) was initiated with a Buy at BofA/Merrill, a Buy at Canaccord, and an Outperform at Cowen. 4. WildHorse Resource (WRD) was initiated with an Overweight at Barclays, an Overweight at Piper Jaffray, an Outperform at Wells Fargo, a Buy at BofA/Merrill, a Buy at Guggenheim, and an Outperform at BMO Capital. 5. Hormel Foods (HRL) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ALDX Aldeyra

07/01/16
STFL
07/01/16
INITIATION
Target $5.5
STFL
Buy
Aldeyra initiated with a Buy at Stifel
Stifel analyst Adam Walsh initiated Aldeyra with a Buy and $5.50 price target saying its novel aldehyde trap platform has broad applicability in inflammatory diseases and holds promise for treating rare genetic disorders of aldehyde metabolism.
09/26/16
HCWC
09/26/16
INITIATION
Target $18
HCWC
Buy
Aldeyra initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Aldeyra Therapeutics with an Outperform rating and $18 price target. Few on Wall Street appreciate how large the market could be for Aldeyra's NS2 "aldehyde trap," Davis tells investors in a research note.
07/01/16
07/01/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Canaccord, with analyst Michael Graham noting the stock's 30% decline since last December. Graham sees a long runway for international subscriber growth and believes it will be a key metric through next year at least. 2. GameStop (GME) initiated with an Outperform at Macquarie, with analyst Ben Schachter saying he believes the shift to digital will be somewhat gradual, and GameStop's experienced management team will be able to generate significant cash from its existing business, even as the model evolves into a more diversified multi-channel/multi-category retailer. 3. Concert Pharmaceuticals (CNCE) initiated with a Buy at Stifel, with analyst Adam Walsh saying his bullish thesis centers on two key pipeline assets: AVP-786 in P3 trials for Alzheimer's agitation; and CTP-543, in P1 studies for alopecia areata. Both drugs have blockbuster potential in his view, targeting unmet medical needs with no approved treatments. 4. Aldeyra (ALDX) initiated with a Buy at Stifel, with analyst Adam Walsh saying its novel aldehyde trap platform has broad applicability in inflammatory diseases and holds promise for treating rare genetic disorders of aldehyde metabolism. 5. Celanese (CE) initiated with a Positive at Susquehanna, reflecting the stock's current risk/reward. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
HRC Hill-Rom
$65.55

-0.58 (-0.88%)

02/08/17
LEHM
02/08/17
INITIATION
Target $70
LEHM
Overweight
Hill-Rom initiated with an Overweight at Barclays
Barclays analyst Matthew Taylor started Hill-Rom with an Overweight rating and $70 price target.
01/23/17
STFL
01/23/17
INITIATION
Target $70
STFL
Buy
Hill-Rom initiated with a Buy at Stifel
Stifel initiated Hill-Rom with a Buy and a $70 price target.
09/23/16
RHCO
09/23/16
NO CHANGE
RHCO
Compass Diversified deal should remove 'key overhang,' says SunTrust
After Compass agreed to sell its Tridein Medical unit to Hill-Rom (HRC), SunTrust analyst Douglas Mewhirter says that Tridein is a "small but troublesome portfolio company." He thinks the deal removes a "key overhang" on Compass, and he reiterates a Buy rating on the stock.
07/19/16
MSCO
07/19/16
NO CHANGE
MSCO
Morgan Stanley's highest conviction stocks into earnings
Morgan Stanley highlighed 14 stocks with the highest analyst conviction into earnings. The firm's analyst view earnings as a positive catalyst for BankUnited (BKU), Concho Resources (CXO), Hill-Rom (HRC), lululemon (LULU), Microsoft (MSFT), NXP Semiconductors (NXPI), Pfizer (PFE), Priceline (PCLN), and Sherwin-Williams (SHW) and sees earnings as a negative catslyst for Gilead (GILD), Nordstrom (JWN), Rackspace (RAX), Relypsa (RLYP), and United Natural Foods (UNFI).
ITEK Inotek Pharmaceuticals

12/01/16
ROTH
12/01/16
INITIATION
Target $10
ROTH
Buy
Inotek Pharmaceuticals initiated with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yani started Inotek Pharmaceuticals with a Buy rating and $10 price target, saying its trabodenoson has the potential to become the go-to adjunctive therapy for glaucoma patients who are uncontrolled with or cannot tolerate prostaglandins, potentially capturing a significant portion of second-line prescriptions.
01/04/17
ROTH
01/04/17
NO CHANGE
Target $3
ROTH
Buy
Inotek Pharmaceuticals price target lowered to $3 from $10 at Roth Capital
Roth Capital analyst Sa'ar Yaniv lowered his price target for Inotek Pharmaceuticals to $3 from $10 after its MATrX-1 failed to demonstrate statistically significant decrease in intraocular pressure in glaucoma patients compared with placebo. Despite the "disappointing setback," the analyst believes that value remains in the trabodenoson franchise. He reiterates a Buy rating on the shares.
12/20/16
ADAM
12/20/16
INITIATION
Target $20
ADAM
Buy
Inotek Pharmaceuticals assumed with a Buy at Canaccord
Canaccord analyst Dewy Steadman assumed Inotek Pharmaceuticals with a Buy and $20 price target citing its significant market potential for its trabodenoson monotherapy and combination therapy with the prostaglandin analog latanoprost.
01/03/17
PIPR
01/03/17
DOWNGRADE
PIPR
Neutral
Inotek Pharmaceuticals downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer downgraded Inotek Pharmaceuticals to Neutral saying that while timolol appeared active in the Phase III MATrX-1 study, only the highest dose of tranodenoson came close but still missed the primary endpoint. The analyst wants to see "clearer path towards clinical, regulatory and commercial success" before recommending the shares. He cut his price target for the shares to $3 from $24. Inotek is down 63%, or $3.85, to $2.25 in pre-market trading.
EPZM Epizyme
$15.00

1.15 (8.30%)

08/09/16
LEER
08/09/16
NO CHANGE
Target $39
LEER
Outperform
Epizyme weakness unwarranted, says Leerink
Leerink analyst Seamus Fernandez says Epizyme announced during its Q2 earnings call that it now plans to report results from its two ongoing Phase 2 trials of tazemetostat in the first half of 2017, rather than at medical conferences in late 2016 as previously anticipated. The analyst believes the delay may allow for data to mature and says the weakness in the stock is unwarranted. Fernandez reiterates an Outperform rating and $39 price target on the shares.
09/21/16
09/21/16
NO CHANGE

Epizyme collaborates with Foundation Medicine for tazemetostat Phase 2 trial
Epizyme (EPZM) has entered into a collaboration agreement with Foundation Medicine FMI) to support patient identification and enrollment for Epizyme's ongoing Phase 2 clinical trial of tazemetostat in patients with non-Hodgkin lymphoma. Foundation Medicine's SmartTrials Precision Enrollment Program and FoundationOne Heme panel will assist in identifying a population of individuals with NHL who harbor EZH2 mutations and constitute specific cohorts in the Epizyme trial. Tazemetostat is Epizyme's oral, first-in-class EZH2 inhibitor being investigated in multiple ongoing clinical trials. Early clinical data suggest tazemetostat has encouraging clinical activity and a favorable safety profile in patients with relapsed and refractory NHL.
04/05/16
04/05/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Epizyme (EPZM) initiated with a Buy at Citi by analyst Robyn Karnauskas, who said long-term platform valuation could come in 2017. 2. AT&T (T) initiated with an Outperform at Macquarie. 3. General Dynamics (GD) initiated with a Buy at Guggenheim. 4. Grainger (GWW) initiated with an Outperform at BMO Capital. 5. McDonald's (MCD) initiated with a Hold at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/20/16
RBCM
06/20/16
NO CHANGE
RBCM
Epizyme data could improve over time, says RBC Capital
After the overall response rate of refractory non-Hodgkin lymphoma patients taking Epizyme's Tazemetostat came in at 28%, down from 56% and 60% in prior trials, RBC Capital says that the data could improve over time. Specifically, the firm thinks that some of the patients whose tumors shrunk may become responsive over the longer term. Additionally, RBC Capital reports that there was a 100% overall response rate in the FL EZH2 mutant arm of the trial. The firm keeps an Outperform rating on the shares.
LBIO Lion Biotechnologies
$7.65

-0.4 (-4.97%)

06/10/16
FBRC
06/10/16
NO CHANGE
Target $20
FBRC
Outperform
FBR adds Corium to Alpha Generator list, removes Lion
FBR Capital analyst Ed White added Corium (CORI) to his firm's Alpha Generator list while removing Lion Biotechnologies (LBIO). Corium is being underestimated by the Street as its management has a well-strategized plan to bring Corplex donepezil and Corplex memantine to market, White contends. He has an Outperform rating on the shares with a $20 price target. The analyst lowered his price target for Lion to $18 following the closing of its private financing. He reiterates an Outperform rating on the shares, however, saying it remains one of his top picks.
07/08/16
ROTH
07/08/16
NO CHANGE
Target $15
ROTH
Buy
Lion T cell therapies not that similar to Juno candidate, says Roth Capital
Roth Capital analyst Joseph Pantginis says yesterday's announcement that the Phase II study of Juno Therapeutic's (JUNO) lead candidate, JCR015, was suspended over the deaths of two patients had ripple effects on the space. However, the analyst points out that while both JCR015 and Lion Biotechnologies' (LBIO) LN-144 are T cell therapies with similar preconditioning regimens, the similarities end there. Lion's T cell therapies have not demonstrated characteristic safety profiles of concern, Pantginis tells investors in a research note. He reiterates a Buy rating and $15 on Lion's shares.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
LMAT LeMaitre
$22.26

0.14 (0.63%)

02/22/17
ROTH
02/22/17
NO CHANGE
Target $26
ROTH
Buy
Roth Capital remains a buyer of LeMaitre after results
Roth Capital analyst Chris Lewis notes that LeMaitre's light Q4 was surprising considering its recent string of beat and raise quarters. Nonetheless, the analyst says that his thesis on LeMaitre, which is founded on above average top-line growth, expanding margins/profitability, and a strong balance sheet/cash flow to support accretive M&A, remains intact. Lewis is confident in the company's ability to deliver sustainable 10% revenue growth and 20% operating income growth, as the 2017 guidance implies. He reiterates a Buy rating and $26 price target on the shares.
02/22/17
ADAM
02/22/17
NO CHANGE
Target $27
ADAM
Buy
LeMaitre pullback would be buying opportunity, says Canaccord
Canaccord analyst Jason Mills raised his price target on Lemaitre following mixed Q4 results and he said he would be constructive on any pullback in the shares. He said company guidance suggests business remains solid and would look to put new money to work on any Q4 driven pullbacks in the stock. Mills reiterated his Buy rating and raised his price target to $27 from $25 on LeMaitre shares.
02/22/17
BRRR
02/22/17
DOWNGRADE
BRRR
Market Perform
LeMaitre downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded LeMaitre Vascular to Market Perform saying the shares are likely to "take a pause" now that the company's beat-and-raise streak is broken.
12/20/16
ROTH
12/20/16
NO CHANGE
Target $26
ROTH
Buy
LeMaitre price target raised to $26 from $21.50 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for LeMaitre to $26 from $21.50 to reflect the company's acquisition of Restore Flow Allografts. The analyst believes Restore's cryopreserved allograft offering is a nice fit to LeMaitre's expanding biologics product portfolio and expects the latter to be able to leverage its "strong" direct sales channel focusing solely on the vascular surgeon. He reiterates a Buy rating on LeMaitre's shares.
ADRO Aduro Biotech

05/17/16
JANY
05/17/16
NO CHANGE
Target $22
JANY
Buy
Aduro study failure has limited read-through to Advaxis, says Janney Capital
Janney Capital analyst Roy Buchanan said the failure of a trial Aduro Biotech's (ADRO) listeria-based immunotherapy candidate in advanced pancreatic cancer should have limited read-through to Advaxis' (ADXS) own listeria-based immunotherapy program. The lead indications for Advaxis, including HPV-driven cervical cancer, have good rationale that the HPV is causative, Buchanan tells investors. The analyst keeps a Buy rating and $22 fair value estimate on Advaxis shares.
10/25/16
ROTH
10/25/16
NO CHANGE
Target $20
ROTH
Buy
Aduro Biotech LADD platform takes another perception knock, says Roth Capital
Roth Capital analyst Joseph Pantginis says Aduro Biotech's LADD platform took another perception knock with a second case of a patient's treatment port testing positive for listeria. While there was no listeriosis/systemic impact to the patient and it resolved quickly, a partial clinical hold has been put in place with no new enrollment in LADD studies until protocols are modified with the FDA for increased surveillance. The analyst says his confidence remains high on the LADD platform and reiterates a Buy rating on the stock. Nonetheless, he lowered his price target on the shares to $20 from $22.
05/17/16
ADAM
05/17/16
NO CHANGE
Target $30
ADAM
Buy
Aduro Biotech price target lowered to $30 from $43 at Canaccord
Canaccord lowered its price target on Aduro Biotech to $30 from $43 after its pancreatic cancer drug missed its primary endpoints in a Phase IIb study. The firm said there is potential for its STELLAR drug trial to still succeed, but lowered the probability and thus the price target. Canaccord maintained its Buy rating on Aduro Biotech shares.
05/16/16
ROTH
05/16/16
NO CHANGE
Target $22
ROTH
Buy
Roth cuts Aduro target to $22, takes off Focus List
Roth Capital analyst Joseph Pantginis lowered his price target for Aduro Biotech to $22 from $46 and removed the stock from his firm's Focus List after the company announced that its Phase IIb study did not meet its overall survival endpoint in third-line and greater pancreatic cancer. The analyst keeps a Buy rating on Aduro, however, seeing upside from future pipeline contributions and signed partnerships with its Listeria-based LADD technology. The stock is down 18%, or $1.89, to $8.80 in afternoon trading.

TODAY'S FREE FLY STORIES

CXP

Columbia Property

$21.68

-0.27 (-1.23%)

20:50
03/27/17
03/27
20:50
03/27/17
20:50
Upgrade
Columbia Property rating change  »

Columbia Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

SPG

Simon Property

$166.15

-1.8 (-1.07%)

20:45
03/27/17
03/27
20:45
03/27/17
20:45
Conference/Events
Simon Property management to meet with Canaccord »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 27

    Apr

HALO

Halozyme

$14.27

0.74 (5.47%)

20:41
03/27/17
03/27
20:41
03/27/17
20:41
Conference/Events
Halozyme management to meet with Canaccord »

Meeting to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 01

    Apr

  • 06

    Jun

AYR

Aircastle

$23.44

0.03 (0.13%)

20:38
03/27/17
03/27
20:38
03/27/17
20:38
Conference/Events
Aircastle management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

NEE

NextEra Energy

$131.10

-1.7 (-1.28%)

20:30
03/27/17
03/27
20:30
03/27/17
20:30
Conference/Events
NextEra Energy management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

M

Macy's

$27.93

-0.24 (-0.85%)

20:26
03/27/17
03/27
20:26
03/27/17
20:26
Conference/Events
Macy's management to meet with Guggenheim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

PPBI

Pacific Premier

$36.35

-0.05 (-0.14%)

, HEOP

Heritage Oaks

$12.62

0.02 (0.16%)

20:25
03/27/17
03/27
20:25
03/27/17
20:25
Conference/Events
Heritage Oaks to host special shareholder meeting »

Special Shareholder…

PPBI

Pacific Premier

$36.35

-0.05 (-0.14%)

HEOP

Heritage Oaks

$12.62

0.02 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 27

    Mar

  • 15

    May

CCL

Carnival

$58.87

0.27 (0.46%)

, MKC

McCormick

$101.36

0.35 (0.35%)

20:25
03/27/17
03/27
20:25
03/27/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$58.87

0.27 (0.46%)

MKC

McCormick

$101.36

0.35 (0.35%)

DRI

Darden

$75.58

-1.13 (-1.47%)

FDS

FactSet

$174.55

-2.18 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 28

    Mar

  • 29

    Mar

  • 04

    Apr

  • 03

    May

SYY

Sysco

$52.04

-0.77 (-1.46%)

20:17
03/27/17
03/27
20:17
03/27/17
20:17
Conference/Events
Sysco management to meet with Guggenheim »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 29

    Mar

  • 20

    Jun

MNK

Mallinckrodt

$44.33

1.24 (2.88%)

20:13
03/27/17
03/27
20:13
03/27/17
20:13
Conference/Events
Mallinckrodt management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 08

    May

OGE

OGE Energy

$35.41

-0.28 (-0.78%)

20:10
03/27/17
03/27
20:10
03/27/17
20:10
Conference/Events
OGE Energy management to meet with Guggenheim »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

CMCSA

Comcast

$37.11

-0.27 (-0.72%)

, CMCSK

Comcast

20:03
03/27/17
03/27
20:03
03/27/17
20:03
Periodicals
Comcast to expand streaming video service, Reuters says »

Comcast plans to rebrand…

CMCSA

Comcast

$37.11

-0.27 (-0.72%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAR

Marriott

$93.17

-0.33 (-0.35%)

20:02
03/27/17
03/27
20:02
03/27/17
20:02
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Mar

FBR

Fibria Celulose

$8.67

-0.22 (-2.47%)

19:58
03/27/17
03/27
19:58
03/27/17
19:58
Conference/Events
Fibria Celulose management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Mar

DXC

DXC Technology

, HPE

HP Enterprise

$22.72

-0.05 (-0.22%)

19:51
03/27/17
03/27
19:51
03/27/17
19:51
Initiation
DXC Technology, HP Enterprise, CSC initiated at Goldman »

DXC Technology initiated…

DXC

DXC Technology

HPE

HP Enterprise

$22.72

-0.05 (-0.22%)

CSC

CSC

$68.05

0.35 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 29

    Mar

  • 29

    Mar

  • 06

    Apr

  • 11

    Apr

  • 12

    Apr

  • 13

    Apr

  • 02

    May

  • 12

    Jun

TRI

Thomson Reuters

$43.56

-0.19 (-0.43%)

19:51
03/27/17
03/27
19:51
03/27/17
19:51
Conference/Events
Thomson Reuters management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 28

    Apr

FIS

FIS

$80.41

0.29 (0.36%)

19:48
03/27/17
03/27
19:48
03/27/17
19:48
Downgrade
FIS rating change at Goldman »

FIS downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COUP

Coupa Software

$24.00

0.12 (0.50%)

19:48
03/27/17
03/27
19:48
03/27/17
19:48
Conference/Events
Coupa Software management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

  • 06

    Apr

ALK

Alaska Air

$95.00

0.3 (0.32%)

19:44
03/27/17
03/27
19:44
03/27/17
19:44
Conference/Events
Alaska Air management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

  • 04

    May

TIVO

TiVo

19:40
03/27/17
03/27
19:40
03/27/17
19:40
Conference/Events
TiVo management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 10

    May

TSN

Tyson Foods

$61.84

-0.73 (-1.17%)

, SAFM

Sanderson Farms

$102.76

2.41 (2.40%)

19:40
03/27/17
03/27
19:40
03/27/17
19:40
Hot Stocks
Georgia finds 'low pathogenic' bird flu in commercial flock »

The Georgia Department of…

TSN

Tyson Foods

$61.84

-0.73 (-1.17%)

SAFM

Sanderson Farms

$102.76

2.41 (2.40%)

PPC

Pilgrim's Pride

$22.31

0.05 (0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 20

    Jun

KR

Kroger

$28.93

-0.17 (-0.58%)

19:37
03/27/17
03/27
19:37
03/27/17
19:37
Conference/Events
Kroger management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 30

    Mar

VALE

Vale

$9.34

0.04 (0.43%)

19:30
03/27/17
03/27
19:30
03/27/17
19:30
Hot Stocks
Vale says Fabio Schvartsman appointed as CEO »

Vale announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSM

Nationstar

$15.05

0.1 (0.67%)

19:21
03/27/17
03/27
19:21
03/27/17
19:21
Initiation
Nationstar initiated at Wedbush »

Nationstar initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LNVGY

Lenovo

$12.57

-0.03 (-0.24%)

19:14
03/27/17
03/27
19:14
03/27/17
19:14
Periodicals
Lenovo, Fujitsu postpone PC tie-up, Nikkei says »

Lenovo and Fujitsu will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.